---
title: "Beta Drugs Ltd (BETA) — Share Price, Financials & Analysis"
symbol: "BETA"
company: "Beta Drugs Ltd"
canonical: "https://tapetide.com/stocks/BETA"
isin: "INE351Y01019"
nse_symbol: "BETA"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 2282.69
generated_at: "2026-09-13T19:35:53.494Z"
---

# Beta Drugs Ltd (BETA)

Canonical page: https://tapetide.com/stocks/BETA

## Company

- **NSE Symbol:** BETA
- **ISIN:** INE351Y01019
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-11-24
- **CEO:** Mr. Rahul Batra
- **Employees:** 399
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** betadrugslimited.com

## About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

## Latest Price

- **Price:** ₹2118.5
- **Change:** +32.7 (+1.57%)
- **Open:** ₹2070
- **Day High:** ₹2147.8
- **Day Low:** ₹2013.8
- **Previous Close:** ₹2085.8
- **Volume:** 18068
- **As Of:** 2026-09-11T09:59:41+00:00

## Key Fundamentals

Observed at 2026-09-11T04:38:30.461545Z.

- **Market Cap:** ₹2282.69 Cr
- **Classification:** Microcap
- **P/E (reported):** 50
- **P/E (TTM):** 48.49
- **EPS (TTM):** ₹43.69
- **Book Value:** ₹221.65
- **Price to Book:** 9.41
- **Dividend Yield:** 0%
- **ROE:** 21.52%
- **ROCE:** 19.18%
- **Debt to Equity:** 0.6
- **Revenue (yearly):** ₹384.83 Cr
- **Net Income:** ₹41.48 Cr
- **EBITDA:** ₹75.68 Cr
- **52-Week High:** ₹2807.9
- **52-Week Low:** ₹990.1
- **RSI (14):** 39.83

## Tapetide Score

- **Score:** 43 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 22.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 44.42 | 9% |
| growth | 23.93 | 9% |
| momentum | 87.88 | 12% |
| ownership | 44.2 | 24% |
| quality | 60.91 | 22% |
| valuation | 26.64 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 8.77 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.53%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 16.84% | 54.58% | 94.3% |
| ebitda margin growth | 40.78% | -13.02% | -7.46% | -18.82% |
| net income growth | 81.32% | -2.17% | 11% | 29% |
| revenue growth | 31.3% | 4.35% | 19% | 27% |
| roce | 55.99% | -36.99% | -40.25% | 27.36% |
| roe | 82.21% | -7.2% | 23.24% | 25.92% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 |
| OPM % | 21 | 18 | 20 | 21 | 19 | 19 | 22 |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 |
| Tax % | 25 | 26 | 25 | 26 | 19 | 24 | 25 |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.4 | 8.93 | 14.25 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 | 410 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 | 327 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 83 |
| OPM % | 19 | 18 | 20 | 21 | 23 | 23 | 20 | 21 | 20 | 20 |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 10 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 15 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 61 |
| Tax % | 1 | -2 | 21 | 27 | 28 | 25 | 25 | 26 | 24 | — |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 46 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.6 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 | 43.69 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Cash from Investing Activity | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Cash from Financing Activity | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 | -22 |
| Free Cash Flow | 9 | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
| CFO/OP | 181 | 1 | 47 | 75 | 69 | 44 | 52 | 48 | 49 |

### Ratios

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 | 113 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 | 97 |
| ROCE % | — | 18 | 21 | 22 | 36 | 34 | 33 | 27 | 19 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.9% | 66.73% | 59.1% |
| FIIs | 0% | 0.32% | 0% | 0% | 1.16% | 1.15% | 0% | 0% | 0% | 1.14% | 0.9% | 1.02% |
| DIIs | 0% | 0.02% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 1.89% | 0.29% | 6.23% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 22.37% | 22.33% | 22.35% | 21.96% | 21.7% | 21.6% | 21.81% | 21.75% | 21.81% | 21.78% | 21.81% | 24.3% |
| Others | 10.9% | 10.6% | 10.91% | 11.31% | 10.4% | 10.51% | 11.45% | 11.51% | 11.45% | 10.29% | 10.26% | 9.35% |
| No. of Shareholders | 1722 | 1928 | 2116 | 2323 | 2567 | 2882 | 3045 | 3139 | 3184 | 3694 | 3184 | 7359 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 5 / 6 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2165.67 | Sell |
| EMA (10) | 2161.65 | Sell |
| SMA (20) | 2235.85 | Sell |
| EMA (20) | 2217.01 | Sell |
| SMA (50) | 2292.73 | Sell |
| EMA (50) | 2191.14 | Sell |
| SMA (100) | 1929.7 | Buy |
| EMA (100) | 2016.19 | Buy |
| SMA (200) | 1666.93 | Buy |
| EMA (200) | 1842.23 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 42.31 | Neutral |
| MACD (12,26,9) | -55.29 | Sell |
| Stochastic (14,3,3) | 13.91 | Buy |
| ADX (14) | 14.3 | Neutral |
| Williams %R (14) | -71.95 | Neutral |
| ATR (14) | 120.62 | High Volatility |
| ROC (12) | -6.3 | Sell |
| Stoch RSI (14) | 29.52 | Neutral |
| UO (7,14,28) | 46.71 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BETA_10092026151451_virtual_meet_invitation.pdf) |
| 2026-09-07 | [Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BETA_07092026103354_letter_newspaper.pdf) |
| 2026-09-05 | [Shareholders meeting](https://nsearchives.nseindia.com/corporate/BETA_05092026161612_NOTICE_AGM_FINAL.pdf) |
| 2026-09-03 | [General Updates](https://nsearchives.nseindia.com/corporate/BETA_03092026180926_BOOK_CLOSURE.pdf) |
| 2026-09-03 | [Shareholders meeting](https://nsearchives.nseindia.com/corporate/BETA_03092026180425_NOTICE_OF_AGM.pdf) |
| 2026-08-14 | [Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/BETA_14082026122803_monitoring_agency_report.pdf) |
| 2026-07-23 | [Reply to Clarification- Financial results](https://nsearchives.nseindia.com/corporate/BETA_23072026103522_reply_to_nse.pdf) |
| 2026-07-20 | [Statement of deviation(s) or variation(s) under Reg. 32](https://nsearchives.nseindia.com/corporate/BETA_20072026150821_STATEMENT_OF_DEVIATION_AND_VARIATION.pdf) |
| 2026-07-07 | [Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/BETA_07072026104252_Regulation-74_5_.pdf) |
| 2026-06-30 | [Trading Window](https://nsearchives.nseindia.com/corporate/BETA_30062026125828_trading_window_letter.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_03092026175522_outcome_of_board_meeting.pdf) |
| 2026-08-18 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_18082026120648_outcome_of_board_meeting.pdf) |
| 2026-07-20 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_20072026085813_financial_results_30_june_2026.pdf) |
| 2026-05-25 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_25052026121018_nse_letter_bod_25_may.pdf) |
| 2026-05-14 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_14052026151131_final_results.pdf) |
| 2026-04-25 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_25042026135833_nse_outcome_final.pdf) |
| 2026-02-14 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_14022026133437_FINAL_RESULTS_DEC_NSE.pdf) |
| 2026-01-09 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_09012026171445_board_outcome_final.pdf) |
| 2025-11-29 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BETA_29112025105502_bod_outcome.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Allotment of equity shares under ESOP scheme of the Bank | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 9h - Allotment of equity shares under ESOP scheme of the Bank](https://www.bseindia.com/xml-data/corpfiling/AttachLive/768a524d-c0fb-41a5-9bf5-7c004c939319.pdf) |
| 5 Feb - Allotment of equity shares under ESOP scheme of the Bank | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 5 Feb - Allotment of equity shares under ESOP scheme of the Bank](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43031f3f-b8c7-4deb-bd31-e8aacf0d1b56.pdf) |
| 31 Aug - Board meeting on 3 September 2026 to fix 21st AGM, approve notice and FY26 Directors’ Report. | [Board Meeting - Other business matters 31 Aug - Board meeting on 3 September 2026 to fix 21st AGM, approve notice and FY26 Directors’ Report.](https://nsearchives.nseindia.com/corporate/BETA_31082026120939_BOD_INTIMATION.pdf) |
| 31 Aug - BETA DRUGS LIMITED has informed about Board Meeting to be held on 03-Sep-2026 to consider Other business. | [Board Meeting - Intimation 31 Aug - BETA DRUGS LIMITED has informed about Board Meeting to be held on 03-Sep-2026 to consider Other business.](https://nsearchives.nseindia.com/corporate/ixbrl/PRIOR_INTIMATION_15527_20260831_120156575_WEB.html) |
| 29 Jan - Ujjivan SFB investor meetings scheduled Feb 4, 9, 10, 25 at conferences (Bangalore, Mumbai); no UPSI will be shared. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 29 Jan - Ujjivan SFB investor meetings scheduled Feb 4, 9, 10, 25 at conferences (Bangalore, Mumbai); no UPSI will be shared.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/58bcedce-b918-434c-8c92-5b99bb76d6f9.pdf) |
| 27 Feb - Aniruddha Paul appointed Independent Director; postal ballot passed with 79,40,87,846 votes in favor. | [Scrutinizer Report And Voting Results Of Postal Ballot 27 Feb - Aniruddha Paul appointed Independent Director; postal ballot passed with 79,40,87,846 votes in favor.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6d653cf5-13e6-4147-aa67-3687f495554d.pdf) |
| 22 Jul - Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On … | [Clarification - Financial Results 22 Jul - Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …](https://www.nseindia.com/get-quotes/equity?symbol=BETA) |
| 21 Jul - Beta Drugs published Q1 FY27 unaudited standalone and consolidated results on 21 July 2026. | [Copy of Newspaper Publication 21 Jul - Beta Drugs published Q1 FY27 unaudited standalone and consolidated results on 21 July 2026.](https://nsearchives.nseindia.com/corporate/BETA_21072026115815_advt.pdf) |
| 2 Mar - Investor meetings: 5 Mar 2026 (Birla Mutual Fund, Bangalore) and 9 Mar 2026 (Bharat Connect, virtual). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Mar - Investor meetings: 5 Mar 2026 (Birla Mutual Fund, Bangalore) and 9 Mar 2026 (Bharat Connect, virtual).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5da42724-1891-4d21-8d6b-f2f314cd4142.pdf) |
| 2 Feb - Mr. Mohd Shakil Khan appointed Head of Collections effective February 02, 2026; 25+ years credit risk experience. | [Announcement under Regulation 30 (LODR)-Change in Management 2 Feb - Mr. Mohd Shakil Khan appointed Head of Collections effective February 02, 2026; 25+ years credit risk experience.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6640b386-0299-4852-9acf-bbfa45ec3f6c.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-27 | [Investor Presentation](https://nsearchives.nseindia.com/corporate/BETA_27072026212351_Beta_Drugs_Ltd_Investor_Presentation_July_26.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-05-22 | [Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BETA_22052026202630_transcript.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-05-15 | [Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BETA_15052026165741_10043001.zip) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/AR_31535_BETA_2025_2026_A_10632227_05092026162411.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28583_BETA_2024_2025_A_5408479_05092025164526.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25848_BETA_2023_2024_05092024173743.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_23545_BETA_2022_2023_05092023183446_09052023190021.zip) |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/SME_AR_21387_BETA_2021_2022_05092022181412_09052022190034.zip) |
| from nse | [Annual Report 2021 from nse](https://archives.nseindia.com/annual_reports/SME_AR_19682_BETA_2020_2021_07092021231540_09082021070006.zip) |
| from nse | [Annual Report 2020 from nse](https://archives.nseindia.com/annual_reports/SME_AR_17503_BETA_2019_2020_07092020145918_07092020150004.zip) |
| from nse | [Annual Report 2019 from nse](https://archives.nseindia.com/annual_reports/SME_AR_15822_BETA_2018_2019_05092019182038_05092019190002.zip) |
| from nse | [Annual Report 2018 from nse](https://archives.nseindia.com/annual_reports/SME_AR_13779_BETA_2017_2018_29092018121056.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/10c36c30-fd8e-4a2b-b12d-c5f1074bbed9.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/058c652d-94e3-4b6c-b450-a85a83119c8a.pdf) |
| Oct 2025 | [Concall - Oct 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/16fe5ee5-a06d-49e9-af74-86892085f08c.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f52da29f-adfb-4c01-b43c-26e57f6ffd8d.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/46ed0584-f793-4610-8803-eeaeced7420b.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/BETA_13112025152041_TRANSCRIPT.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/BETA_14112024164049_TRANSCRIPTNSE.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://nsearchives.nseindia.com/corporate/BETA_23112023104630_transcriptconcall.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://archives.nseindia.com/corporate/BETA_07112022163203_transcript.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f84953ef-14d2-4590-8b47-ff5b425926f5.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7ac5eb26-fc8a-447d-bbcd-401633ce2a86.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:35:53.494Z.